{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:45:41Z","timestamp":1792118741267,"version":"4.4.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro,Italy","doi-asserted-by":"crossref","award":["24449"],"award-info":[{"award-number":["24449"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro,Italy","doi-asserted-by":"crossref","award":["24449"],"award-info":[{"award-number":["24449"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro,Italy","doi-asserted-by":"crossref","award":["24449"],"award-info":[{"award-number":["24449"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro,Italy","doi-asserted-by":"crossref","award":["24449"],"award-info":[{"award-number":["24449"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro,Italy","doi-asserted-by":"crossref","award":["24449"],"award-info":[{"award-number":["24449"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e0 degli studi \"Magna Graecia\" di Catanzaro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multiple myeloma (MM) is the second most common hematological malignancy worldwide, characterized by abnormal proliferation of malignant plasma cells within a tumor-permissive bone marrow microenvironment. Metabolic dysfunctions are emerging as key determinants in the pathobiology of MM. In this review, we highlight the metabolic features of MM, showing how alterations in various lipid pathways, mainly involving fatty acids, cholesterol and sphingolipids, affect the growth, survival and drug responsiveness of MM cells, as well as their cross-talk with other cellular components of the tumor microenvironment. These findings will provide a new path to understanding the mechanisms underlying how lipid vulnerabilities may arise and affect the phenotype of malignant plasma cells, highlighting novel druggable pathways with a significant impact on the management of MM.<\/jats:p>","DOI":"10.1007\/s10238-023-01174-2","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T11:03:31Z","timestamp":1693220611000},"page":"3373-3390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Lipid metabolic vulnerabilities of multiple myeloma"],"prefix":"10.1007","volume":"23","author":[{"given":"Roberta","family":"Torcasio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eugenia","family":"Gallo Cantafio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raissa Kaori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Ganino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"1174_CR1","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","volume":"105","author":"A Gulla","year":"2020","unstructured":"Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020;105:2358\u201367. https:\/\/doi.org\/10.3324\/haematol.2020.247015.","journal-title":"Haematologica"},{"key":"1174_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/PPO.0000000000000350","volume":"25","author":"P Kapoor","year":"2019","unstructured":"Kapoor P, Rajkumar SV. Smoldering multiple myeloma. Cancer J. 2019;25:65\u201371. https:\/\/doi.org\/10.1097\/PPO.0000000000000350.","journal-title":"Cancer J"},{"key":"1174_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011;364:1046\u201360. https:\/\/doi.org\/10.1056\/NEJMra1011442.","journal-title":"N Engl J Med"},{"key":"1174_CR4","doi-asserted-by":"publisher","first-page":"155614","DOI":"10.1016\/j.metabol.2023.155614","volume":"145","author":"M Hole\u010dek","year":"2023","unstructured":"Hole\u010dek M. Roles of malate and aspartate in gluconeogenesis in various physiological and pathological states. Metabolism. 2023;145:155614. https:\/\/doi.org\/10.1016\/j.metabol.2023.155614.","journal-title":"Metabolism"},{"key":"1174_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1000106","author":"R Nair","year":"2022","unstructured":"Nair R, Gupta P, Shanmugam M. Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1000106.","journal-title":"Front Oncol"},{"key":"1174_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.604143","author":"A Barbato","year":"2020","unstructured":"Barbato A, Scandura G, Puglisi F, et al. Mitochondrial bioenergetics at the onset of drug resistance in hematological malignancies: an overview. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.604143.","journal-title":"Front Oncol"},{"key":"1174_CR7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008345","author":"S Findlay","year":"2023","unstructured":"Findlay S, Nair R, Merrill RA, et al. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma. Blood Adv. 2023. https:\/\/doi.org\/10.1182\/bloodadvances.2022008345.","journal-title":"Blood Adv"},{"key":"1174_CR8","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1038\/cddis.2013.60","volume":"4","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4:e532\u2013e532. https:\/\/doi.org\/10.1038\/cddis.2013.60.","journal-title":"Cell Death Dis"},{"key":"1174_CR9","doi-asserted-by":"publisher","first-page":"108231","DOI":"10.1016\/j.celrep.2020.108231","volume":"33","author":"KER Hollinshead","year":"2020","unstructured":"Hollinshead KER, Parker SJ, Eapen VV, et al. Respiratory supercomplexes promote mitochondrial efficiency and growth in severely hypoxic pancreatic cancer. Cell Rep. 2020;33:108231. https:\/\/doi.org\/10.1016\/j.celrep.2020.108231.","journal-title":"Cell Rep"},{"key":"1174_CR10","doi-asserted-by":"publisher","DOI":"10.20517\/2394-4722.2019.05","author":"D Rizzieri","year":"2019","unstructured":"Rizzieri D, Paul B, Kang Y. Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma. J Cancer Metastasis Treat. 2019. https:\/\/doi.org\/10.20517\/2394-4722.2019.05.","journal-title":"J Cancer Metastasis Treat"},{"key":"1174_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/metabo11010028","volume":"11","author":"K Ohshima","year":"2021","unstructured":"Ohshima K, Morii E. Metabolic reprogramming of cancer cells during tumor progression and metastasis. Metabolites. 2021;11:28. https:\/\/doi.org\/10.3390\/metabo11010028.","journal-title":"Metabolites"},{"key":"1174_CR12","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1038\/s41467-022-32101-w","volume":"13","author":"Y Tan","year":"2022","unstructured":"Tan Y, Li J, Zhao G, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022;13:4554. https:\/\/doi.org\/10.1038\/s41467-022-32101-w.","journal-title":"Nat Commun"},{"key":"1174_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antiox7010016","volume":"7","author":"Z Zhou","year":"2018","unstructured":"Zhou Z, Ibekwe E, Chornenkyy Y. Metabolic alterations in cancer cells and the emerging role of oncometabolites as drivers of neoplastic change. Antioxidants. 2018;7:16. https:\/\/doi.org\/10.3390\/antiox7010016.","journal-title":"Antioxidants"},{"key":"1174_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-pathmechdis-012419-032711","volume":"15","author":"DC Chan","year":"2020","unstructured":"Chan DC. Mitochondrial dynamics and its involvement in disease. Annu Rev Pathol. 2020;15:235\u201359. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-012419-032711.","journal-title":"Annu Rev Pathol"},{"key":"1174_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13058-020-01301-x","volume":"22","author":"BA Humphries","year":"2020","unstructured":"Humphries BA, Cutter AC, Buschhaus JM, et al. Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer. Breast Cancer Res. 2020;22:60. https:\/\/doi.org\/10.1186\/s13058-020-01301-x.","journal-title":"Breast Cancer Res"},{"key":"1174_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/ncrna9010016","volume":"9","author":"ME Gallo Cantafio","year":"2023","unstructured":"Gallo Cantafio ME, Torcasio R, Viglietto G, Amodio N. Non-coding RNA-dependent regulation of mitochondrial dynamics in cancer pathophysiology. Noncoding RNA. 2023;9:16. https:\/\/doi.org\/10.3390\/ncrna9010016.","journal-title":"Noncoding RNA"},{"key":"1174_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1155621","author":"M Matamala Montoya","year":"2023","unstructured":"Matamala Montoya M, van Slobbe GJJ, Chang J-C, et al. Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1155621.","journal-title":"Front Oncol"},{"key":"1174_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000506174","volume":"143","author":"H Lee","year":"2020","unstructured":"Lee H, Jimenez-Zepeda VH. The prognostic role of lactate dehydrogenase at first relapse of multiple myeloma. Acta Haematol. 2020;143:516\u20137. https:\/\/doi.org\/10.1159\/000506174.","journal-title":"Acta Haematol"},{"key":"1174_CR19","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/leu.2016.102","volume":"30","author":"GP Soriano","year":"2016","unstructured":"Soriano GP, Besse L, Li N, et al. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. Leukemia. 2016;30:2198\u2013207. https:\/\/doi.org\/10.1038\/leu.2016.102.","journal-title":"Leukemia"},{"key":"1174_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.leukres.2015.12.008","volume":"41","author":"T Matsumoto","year":"2016","unstructured":"Matsumoto T, Jimi S, Migita K, et al. Inhibition of glucose transporter 1 induces apoptosis and sensitizes multiple myeloma cells to conventional chemotherapeutic agents. Leuk Res. 2016;41:103\u201310. https:\/\/doi.org\/10.1016\/j.leukres.2015.12.008.","journal-title":"Leuk Res"},{"key":"1174_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94543","author":"WI Gonsalves","year":"2018","unstructured":"Gonsalves WI, Ramakrishnan V, Hitosugi T, et al. Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.94543.","journal-title":"JCI Insight"},{"key":"1174_CR22","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","volume":"5","author":"ZE Stine","year":"2015","unstructured":"Stine ZE, Walton ZE, Altman BJ, et al. MYC, Metabolism, and Cancer. Cancer Discov. 2015;5:1024\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0507.","journal-title":"Cancer Discov"},{"key":"1174_CR23","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/s41375-018-0036-x","volume":"32","author":"KK Jovanovi\u0107","year":"2018","unstructured":"Jovanovi\u0107 KK, Roche-Lestienne C, Ghobrial IM, et al. Targeting MYC in multiple myeloma. Leukemia. 2018;32:1295\u2013306. https:\/\/doi.org\/10.1038\/s41375-018-0036-x.","journal-title":"Leukemia"},{"key":"1174_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","volume":"34","author":"K Misund","year":"2020","unstructured":"Misund K, Keane N, Stein CK, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia. 2020;34:322\u20136. https:\/\/doi.org\/10.1038\/s41375-019-0543-4.","journal-title":"Leukemia"},{"key":"1174_CR25","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14728222.2017.1279148","volume":"21","author":"N Giuliani","year":"2017","unstructured":"Giuliani N, Chiu M, Bolzoni M, et al. The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma. Expert Opin Ther Targets. 2017;21:231\u20134. https:\/\/doi.org\/10.1080\/14728222.2017.1279148.","journal-title":"Expert Opin Ther Targets"},{"key":"1174_CR26","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1038\/onc.2015.464","volume":"35","author":"R Bajpai","year":"2016","unstructured":"Bajpai R, Matulis SM, Wei C, et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene. 2016;35:3955\u201364. https:\/\/doi.org\/10.1038\/onc.2015.464.","journal-title":"Oncogene"},{"key":"1174_CR27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","volume":"5","author":"EA Zaal","year":"2017","unstructured":"Zaal EA, Wu W, Jansen G, et al. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 2017;5:7. https:\/\/doi.org\/10.1186\/s40170-017-0169-9.","journal-title":"Cancer Metab"},{"key":"1174_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00067","author":"C Falank","year":"2016","unstructured":"Falank C, Fairfield H, Reagan MR. Signaling interplay between bone marrow adipose tissue and multiple myeloma cells. Front Endocrinol (Lausanne). 2016. https:\/\/doi.org\/10.3389\/fendo.2016.00067.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1174_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.591342","author":"S Wu","year":"2021","unstructured":"Wu S, Kuang H, Ke J, et al. Metabolic reprogramming induces immune cell dysfunction in the tumor microenvironment of multiple myeloma. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2020.591342.","journal-title":"Front Oncol"},{"key":"1174_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/bjc.2012.527","volume":"108","author":"S Fujiwara","year":"2013","unstructured":"Fujiwara S, Kawano Y, Yuki H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer. 2013;108:170\u20138. https:\/\/doi.org\/10.1038\/bjc.2012.527.","journal-title":"Br J Cancer"},{"key":"1174_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41389-022-00380-z","volume":"11","author":"C Giallongo","year":"2022","unstructured":"Giallongo C, Dulcamare I, Tibullo D, et al. CXCL12\/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. Oncogenesis. 2022;11:6. https:\/\/doi.org\/10.1038\/s41389-022-00380-z.","journal-title":"Oncogenesis"},{"key":"1174_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1053\/j.seminoncol.2014.03.002","volume":"41","author":"U Martinez-Outschoorn","year":"2014","unstructured":"Martinez-Outschoorn U, Sotgia F, Lisanti MP. Tumor Microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol. 2014;41:195\u2013216. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.03.002.","journal-title":"Semin Oncol"},{"key":"1174_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1077768","author":"J Lv","year":"2022","unstructured":"Lv J, Sun H, Gong L, et al. Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1077768.","journal-title":"Front Immunol"},{"key":"1174_CR34","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1016\/j.ajpath.2016.07.012","volume":"186","author":"TN Trotter","year":"2016","unstructured":"Trotter TN, Gibson JT, Sherpa TL, et al. Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone. Am J Pathol. 2016;186:3054\u201363. https:\/\/doi.org\/10.1016\/j.ajpath.2016.07.012.","journal-title":"Am J Pathol"},{"key":"1174_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-022-00303-z","volume":"11","author":"I Oudaert","year":"2022","unstructured":"Oudaert I, Van der Vreken A, Maes A, et al. Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma. Exp Hematol Oncol. 2022;11:49. https:\/\/doi.org\/10.1186\/s40164-022-00303-z.","journal-title":"Exp Hematol Oncol"},{"key":"1174_CR36","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1111\/j.1742-4658.2012.08644.x","volume":"279","author":"CR Santos","year":"2012","unstructured":"Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J. 2012;279:2610\u201323. https:\/\/doi.org\/10.1111\/j.1742-4658.2012.08644.x.","journal-title":"FEBS J"},{"key":"1174_CR37","first-page":"27","volume":"13","author":"G Medes","year":"1953","unstructured":"Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 1953;13:27\u20139.","journal-title":"Cancer Res"},{"key":"1174_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1134154","author":"C Li","year":"2023","unstructured":"Li C, Wang F, Cui L, et al. Association between abnormal lipid metabolism and tumor. Front Endocrinol (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1134154.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1174_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.987499","author":"L Zhang","year":"2022","unstructured":"Zhang L, Chang N, Liu J, et al. Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.987499.","journal-title":"Front Oncol"},{"key":"1174_CR40","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1016\/j.molcel.2021.08.027","volume":"81","author":"H Yoon","year":"2021","unstructured":"Yoon H, Shaw JL, Haigis MC, Greka A. Lipid metabolism in sickness and in health: emerging regulators of lipotoxicity. Mol Cell. 2021;81:3708\u201330. https:\/\/doi.org\/10.1016\/j.molcel.2021.08.027.","journal-title":"Mol Cell"},{"key":"1174_CR41","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12935-022-02645-4","volume":"22","author":"X Liu","year":"2022","unstructured":"Liu X, Zhang P, Xu J, et al. Lipid metabolism in tumor microenvironment: novel therapeutic targets. Cancer Cell Int. 2022;22:224. https:\/\/doi.org\/10.1186\/s12935-022-02645-4.","journal-title":"Cancer Cell Int"},{"key":"1174_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.plipres.2009.12.002","volume":"49","author":"H Guillou","year":"2010","unstructured":"Guillou H, Zadravec D, Martin PGP, Jacobsson A. The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice. Prog Lipid Res. 2010;49:186\u201399. https:\/\/doi.org\/10.1016\/j.plipres.2009.12.002.","journal-title":"Prog Lipid Res"},{"key":"1174_CR43","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3390\/ijms23042170","volume":"23","author":"H Yoon","year":"2022","unstructured":"Yoon H, Lee S. Fatty acid metabolism in ovarian cancer: therapeutic implications. Int J Mol Sci. 2022;23:2170. https:\/\/doi.org\/10.3390\/ijms23042170.","journal-title":"Int J Mol Sci"},{"key":"1174_CR44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1042\/bj20020747","volume":"367","author":"JFF Brinkmann","year":"2002","unstructured":"Brinkmann JFF, Abumrad NA, Ibrahimi A, et al. New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase\/CD36. Biochem J. 2002;367:561\u201370. https:\/\/doi.org\/10.1042\/bj20020747.","journal-title":"Biochem J"},{"key":"1174_CR45","doi-asserted-by":"publisher","first-page":"e10173","DOI":"10.1002\/jbm4.10173","volume":"3","author":"M Masarwi","year":"2019","unstructured":"Masarwi M, DeSchiffart A, Ham J, Reagan MR. Multiple myeloma and fatty acid metabolism. JBMR Plus. 2019;3:e10173. https:\/\/doi.org\/10.1002\/jbm4.10173.","journal-title":"JBMR Plus"},{"key":"1174_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/274585","volume":"2015","author":"S Balaban","year":"2015","unstructured":"Balaban S, Lee LS, Schreuder M, Hoy AJ. Obesity and cancer progression: is there a role of fatty acid metabolism? Biomed Res Int. 2015;2015:1\u201317. https:\/\/doi.org\/10.1155\/2015\/274585.","journal-title":"Biomed Res Int"},{"key":"1174_CR47","doi-asserted-by":"publisher","first-page":"14752","DOI":"10.1038\/srep14752","volume":"5","author":"A Nath","year":"2015","unstructured":"Nath A, Li I, Roberts LR, Chan C. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep. 2015;5:14752. https:\/\/doi.org\/10.1038\/srep14752.","journal-title":"Sci Rep"},{"key":"1174_CR48","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1242\/jcs.03280","volume":"119","author":"K Milger","year":"2006","unstructured":"Milger K, Herrmann T, Becker C, et al. Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J Cell Sci. 2006;119:4678\u201388. https:\/\/doi.org\/10.1242\/jcs.03280.","journal-title":"J Cell Sci"},{"key":"1174_CR49","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1002\/1878-0261.12816","volume":"14","author":"LP Fern\u00e1ndez","year":"2020","unstructured":"Fern\u00e1ndez LP, Merino M, Colmenarejo G, et al. Metabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in non-small cell lung cancer. Mol Oncol. 2020;14:3135\u201352. https:\/\/doi.org\/10.1002\/1878-0261.12816.","journal-title":"Mol Oncol"},{"key":"1174_CR50","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.7150\/ijbs.69802","volume":"18","author":"J Quan","year":"2022","unstructured":"Quan J, Cheng C, Tan Y, et al. Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGF\u03b21-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma. Int J Biol Sci. 2022;18:2484\u201396. https:\/\/doi.org\/10.7150\/ijbs.69802.","journal-title":"Int J Biol Sci"},{"key":"1174_CR51","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.canlet.2020.12.019","volume":"502","author":"J Chen","year":"2021","unstructured":"Chen J, Ding C, Chen Y, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc\/SREBP1 pathway. Cancer Lett. 2021;502:154\u201365. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.019.","journal-title":"Cancer Lett"},{"key":"1174_CR52","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/nu10101383","volume":"10","author":"Z Song","year":"2018","unstructured":"Song Z, Xiaoli A, Yang F. Regulation and metabolic significance of de novo lipogenesis in adipose tissues. Nutrients. 2018;10:1383. https:\/\/doi.org\/10.3390\/nu10101383.","journal-title":"Nutrients"},{"key":"1174_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1129010","author":"Y Yu","year":"2023","unstructured":"Yu Y, Nie Q, Wang Z, et al. Targeting acetyl-CoA carboxylase 1 for cancer therapy. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1129010.","journal-title":"Front Pharmacol"},{"key":"1174_CR54","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.3390\/molecules25173935","volume":"25","author":"CW Fhu","year":"2020","unstructured":"Fhu CW, Ali A. Fatty acid synthase: an emerging target in cancer. Molecules. 2020;25:3935. https:\/\/doi.org\/10.3390\/molecules25173935.","journal-title":"Molecules"},{"key":"1174_CR55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-021-02067-6","volume":"40","author":"F Ascenzi","year":"2021","unstructured":"Ascenzi F, De Vitis C, Maugeri-Sacc\u00e0 M, et al. SCD1, autophagy and cancer: implications for therapy. J Exp Clin Cancer Res. 2021;40:265. https:\/\/doi.org\/10.1186\/s13046-021-02067-6.","journal-title":"J Exp Clin Cancer Res"},{"key":"1174_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12032-022-01904-8","volume":"40","author":"J Chen","year":"2022","unstructured":"Chen J, Lv S, Huang B, et al. Upregulation of SCD1 by ErbB2 via LDHA promotes breast cancer cell migration and invasion. Med Oncol. 2022;40:40. https:\/\/doi.org\/10.1007\/s12032-022-01904-8.","journal-title":"Med Oncol"},{"key":"1174_CR57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-018-0711-9","volume":"37","author":"H Ran","year":"2018","unstructured":"Ran H, Zhu Y, Deng R, et al. Stearoyl-CoA desaturase-1 promotes colorectal cancer metastasis in response to glucose by suppressing PTEN. J Exp Clin Cancer Res. 2018;37:54. https:\/\/doi.org\/10.1186\/s13046-018-0711-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"1174_CR58","doi-asserted-by":"publisher","first-page":"8871","DOI":"10.1007\/s11033-021-07094-2","volume":"49","author":"M Raeisi","year":"2022","unstructured":"Raeisi M, Hassanbeigi L, Khalili F, et al. Stearoyl-CoA desaturase 1 as a therapeutic target for cancer: a focus on hepatocellular carcinoma. Mol Biol Rep. 2022;49:8871\u201382. https:\/\/doi.org\/10.1007\/s11033-021-07094-2.","journal-title":"Mol Biol Rep"},{"key":"1174_CR59","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171:273\u201385. https:\/\/doi.org\/10.1016\/j.cell.2017.09.021.","journal-title":"Cell"},{"key":"1174_CR60","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-19-0369","volume":"79","author":"L Tesfay","year":"2019","unstructured":"Tesfay L, Paul BT, Konstorum A, et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 2019;79:5355\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0369.","journal-title":"Cancer Res"},{"key":"1174_CR61","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/biology10030184","volume":"10","author":"J-Y Lee","year":"2021","unstructured":"Lee J-Y, Kim WK, Bae K-H, et al. Lipid metabolism and ferroptosis. Biology. 2021;10:184. https:\/\/doi.org\/10.3390\/biology10030184.","journal-title":"Biology"},{"key":"1174_CR62","doi-asserted-by":"publisher","first-page":"10021","DOI":"10.1038\/s41598-018-27607-7","volume":"8","author":"A Dihingia","year":"2018","unstructured":"Dihingia A, Bordoloi J, Dutta P, et al. Hexane-Isopropanolic Extract of Tungrymbai, a North-East Indian fermented soybean food prevents hepatic steatosis via regulating AMPK-mediated SREBP\/FAS\/ACC\/HMGCR and PPAR\u03b1\/CPT1A\/UCP2 pathways. Sci Rep. 2018;8:10021. https:\/\/doi.org\/10.1038\/s41598-018-27607-7.","journal-title":"Sci Rep"},{"key":"1174_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2049-3002-1-3","volume":"1","author":"B Griffiths","year":"2013","unstructured":"Griffiths B, Lewis CA, Bensaad K, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013;1:3. https:\/\/doi.org\/10.1186\/2049-3002-1-3.","journal-title":"Cancer Metab"},{"key":"1174_CR64","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1038\/onc.2014.439","volume":"34","author":"CA Lewis","year":"2015","unstructured":"Lewis CA, Brault C, Peck B, et al. SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene. 2015;34:5128\u201340. https:\/\/doi.org\/10.1038\/onc.2014.439.","journal-title":"Oncogene"},{"key":"1174_CR65","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1038\/oncsis.2013.14","volume":"2","author":"TH Beckham","year":"2013","unstructured":"Beckham TH, Cheng JC, Lu P, et al. Acid ceramidase induces sphingosine kinase 1\/S1P receptor 2-mediated activation of oncogenic Akt signaling. Oncogenesis. 2013;2:e49\u2013e49. https:\/\/doi.org\/10.1038\/oncsis.2013.14.","journal-title":"Oncogenesis"},{"key":"1174_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cphy.c170012","volume-title":"Triglyceride metabolism in the liver Comprehensive Physiology","author":"M Alves-Bezerra","year":"2017","unstructured":"Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver Comprehensive Physiology. London: Wiley; 2017. p. 1\u201322."},{"key":"1174_CR67","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0163-7827(03)00051-1","volume":"43","author":"R Coleman","year":"2004","unstructured":"Coleman R. Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res. 2004;43:134\u201376. https:\/\/doi.org\/10.1016\/S0163-7827(03)00051-1.","journal-title":"Prog Lipid Res"},{"key":"1174_CR68","doi-asserted-by":"publisher","first-page":"11430","DOI":"10.3390\/ijms222111430","volume":"22","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou M, Paschou SA, Ntanasis-Stathopoulos I, Dimopoulos MA. Metabolic disorders in multiple myeloma. Int J Mol Sci. 2021;22:11430. https:\/\/doi.org\/10.3390\/ijms222111430.","journal-title":"Int J Mol Sci"},{"key":"1174_CR69","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1182\/blood.2021013832","volume":"139","author":"C Panaroni","year":"2022","unstructured":"Panaroni C, Fulzele K, Mori T, et al. Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins. Blood. 2022;139:876\u201388. https:\/\/doi.org\/10.1182\/blood.2021013832.","journal-title":"Blood"},{"key":"1174_CR70","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.leukres.2014.08.009","volume":"38","author":"A Jurczyszyn","year":"2014","unstructured":"Jurczyszyn A, Czepiel J, Gdula-Argasi\u0144ska J, et al. Erythrocyte membrane fatty acids in multiple myeloma patients. Leuk Res. 2014;38:1260\u20135. https:\/\/doi.org\/10.1016\/j.leukres.2014.08.009.","journal-title":"Leuk Res"},{"key":"1174_CR71","doi-asserted-by":"publisher","first-page":"110870","DOI":"10.1016\/j.celrep.2022.110870","volume":"39","author":"Y-J Li","year":"2022","unstructured":"Li Y-J, Fahrmann JF, Aftabizadeh M, et al. Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids. Cell Rep. 2022;39:110870. https:\/\/doi.org\/10.1016\/j.celrep.2022.110870.","journal-title":"Cell Rep"},{"key":"1174_CR72","doi-asserted-by":"publisher","first-page":"e46484","DOI":"10.1371\/journal.pone.0046484","volume":"7","author":"JM Tirado-V\u00e9lez","year":"2012","unstructured":"Tirado-V\u00e9lez JM, Joumady I, S\u00e1ez-Benito A, et al. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation. PLoS ONE. 2012;7:e46484. https:\/\/doi.org\/10.1371\/journal.pone.0046484.","journal-title":"PLoS ONE"},{"key":"1174_CR73","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood.2022016892","volume":"141","author":"E Morelli","year":"2023","unstructured":"Morelli E, Fulciniti M, Samur MK, et al. A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth. Blood. 2023;141:391\u2013405. https:\/\/doi.org\/10.1182\/blood.2022016892.","journal-title":"Blood"},{"key":"1174_CR74","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.cell.2014.11.020","volume":"159","author":"SA Comerford","year":"2014","unstructured":"Comerford SA, Huang Z, Du X, et al. Acetate dependence of tumors. Cell. 2014;159:1591\u2013602. https:\/\/doi.org\/10.1016\/j.cell.2014.11.020.","journal-title":"Cell"},{"key":"1174_CR75","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature07064","volume":"454","author":"AL Shaffer","year":"2008","unstructured":"Shaffer AL, Emre NCT, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454:226\u201331. https:\/\/doi.org\/10.1038\/nature07064.","journal-title":"Nature"},{"key":"1174_CR76","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cmet.2020.12.011","volume":"33","author":"Z Li","year":"2021","unstructured":"Li Z, Liu H, He J, et al. Acetyl-CoA synthetase 2: a critical linkage in obesity-induced tumorigenesis in myeloma. Cell Metab. 2021;33:78-93.e7. https:\/\/doi.org\/10.1016\/j.cmet.2020.12.011.","journal-title":"Cell Metab"},{"key":"1174_CR77","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2017.05.002","volume":"401","author":"Q Liu","year":"2017","unstructured":"Liu Q, Luo Q, Halim A, Song G. Targeting lipid metabolism of cancer cells: a promising therapeutic strategy for cancer. Cancer Lett. 2017;401:39\u201345. https:\/\/doi.org\/10.1016\/j.canlet.2017.05.002.","journal-title":"Cancer Lett"},{"key":"1174_CR78","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.3324\/haematol.2018.207704","volume":"104","author":"L Besse","year":"2019","unstructured":"Besse L, Besse A, Mendez-Lopez M, et al. A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica. 2019;104:e415\u20139. https:\/\/doi.org\/10.3324\/haematol.2018.207704.","journal-title":"Haematologica"},{"key":"1174_CR79","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1111\/bph.15653","volume":"178","author":"G Xu","year":"2021","unstructured":"Xu G, Huang S, Peng J, et al. Targeting lipid metabolism in multiple myeloma cells: rational development of a synergistic strategy with proteasome inhibitors. Br J Pharmacol. 2021;178:4741\u201357. https:\/\/doi.org\/10.1111\/bph.15653.","journal-title":"Br J Pharmacol"},{"key":"1174_CR80","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1182\/bloodadvances.2020002578","volume":"5","author":"BC Lipchick","year":"2021","unstructured":"Lipchick BC, Utley A, Han Z, et al. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma. Blood Adv. 2021;5:1933\u201346. https:\/\/doi.org\/10.1182\/bloodadvances.2020002578.","journal-title":"Blood Adv"},{"key":"1174_CR81","doi-asserted-by":"publisher","first-page":"106363","DOI":"10.1016\/j.prostaglandins.2019.106363","volume":"144","author":"H Kuwata","year":"2019","unstructured":"Kuwata H, Hara S. Role of acyl-CoA synthetase ACSL4 in arachidonic acid metabolism. Prostaglandins Other Lipid Mediat. 2019;144:106363. https:\/\/doi.org\/10.1016\/j.prostaglandins.2019.106363.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1174_CR82","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1093\/carcin\/bgad015","volume":"44","author":"J Zhang","year":"2023","unstructured":"Zhang J, Liu Y, Li Q, et al. ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis. Carcinogenesis. 2023;44:242\u201351. https:\/\/doi.org\/10.1093\/carcin\/bgad015.","journal-title":"Carcinogenesis"},{"key":"1174_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00224","author":"M Azrad","year":"2013","unstructured":"Azrad M, Turgeon C, Demark-Wahnefried W. Current evidence linking polyunsaturated fatty acids with cancer risk and progression. Front Oncol. 2013. https:\/\/doi.org\/10.3389\/fonc.2013.00224.","journal-title":"Front Oncol"},{"key":"1174_CR84","doi-asserted-by":"publisher","first-page":"7447","DOI":"10.3390\/molecules26247447","volume":"26","author":"N Mahammad","year":"2021","unstructured":"Mahammad N, Ashcroft FJ, Feuerherm AJ, et al. Inhibition of cytosolic phospholipase A2\u03b1 induces apoptosis in multiple myeloma cells. Molecules. 2021;26:7447. https:\/\/doi.org\/10.3390\/molecules26247447.","journal-title":"Molecules"},{"key":"1174_CR85","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1038\/s41467-018-04987-y","volume":"9","author":"KM Gharpure","year":"2018","unstructured":"Gharpure KM, Pradeep S, Sans M, et al. FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun. 2018;9:2923. https:\/\/doi.org\/10.1038\/s41467-018-04987-y.","journal-title":"Nat Commun"},{"key":"1174_CR86","doi-asserted-by":"publisher","first-page":"109336","DOI":"10.1016\/j.cellsig.2019.06.001","volume":"62","author":"IH McKillop","year":"2019","unstructured":"McKillop IH, Girardi CA, Thompson KJ. Role of fatty acid binding proteins (FABPs) in cancer development and progression. Cell Signal. 2019;62:109336. https:\/\/doi.org\/10.1016\/j.cellsig.2019.06.001.","journal-title":"Cell Signal"},{"key":"1174_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.05.011","author":"C Diedrich","year":"2023","unstructured":"Diedrich C, Maksimos M, Azab AK. Fatty acid binding proteins in multiple myeloma. Trends Mol Med. 2023. https:\/\/doi.org\/10.1016\/j.molmed.2023.05.011.","journal-title":"Trends Mol Med"},{"key":"1174_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.667525","author":"H Jia","year":"2021","unstructured":"Jia H, Zhang X, Liu X, et al. FABP5, a novel immune-related mRNA prognostic marker and a target of immunotherapy for multiple myeloma. Front Med (Lausanne). 2021. https:\/\/doi.org\/10.3389\/fmed.2021.667525.","journal-title":"Front Med (Lausanne)"},{"key":"1174_CR89","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-020-00235-2","volume":"5","author":"Y Dong","year":"2020","unstructured":"Dong Y, Tu R, Liu H, Qing G. Regulation of cancer cell metabolism: oncogenic MYC in the driver\u2019s seat. Signal Transduct Target Ther. 2020;5:124. https:\/\/doi.org\/10.1038\/s41392-020-00235-2.","journal-title":"Signal Transduct Target Ther"},{"key":"1174_CR90","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81184","author":"M Farrell","year":"2023","unstructured":"Farrell M, Fairfield H, Karam M, et al. Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signaling. Elife. 2023. https:\/\/doi.org\/10.7554\/eLife.81184.","journal-title":"Elife"},{"key":"1174_CR91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626971","author":"B Guerra","year":"2021","unstructured":"Guerra B, Recio C, Aranda-Tav\u00edo H, et al. The mevalonate pathway, a metabolic target in cancer therapy. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.626971.","journal-title":"Front Oncol"},{"key":"1174_CR92","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cmet.2015.05.014","volume":"21","author":"F Pietrocola","year":"2015","unstructured":"Pietrocola F, Galluzzi L, Bravo-San Pedro JM, et al. Acetyl coenzyme A: a central metabolite and second messenger. Cell Metab. 2015;21:805\u201321. https:\/\/doi.org\/10.1016\/j.cmet.2015.05.014.","journal-title":"Cell Metab"},{"key":"1174_CR93","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrm.2016.67","volume":"17","author":"RG Hodge","year":"2016","unstructured":"Hodge RG, Ridley AJ. Regulating Rho GTPases and their regulators. Nat Rev Mol Cell Biol. 2016;17:496\u2013510. https:\/\/doi.org\/10.1038\/nrm.2016.67.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1174_CR94","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","volume":"21","author":"J Luo","year":"2020","unstructured":"Luo J, Yang H, Song B-L. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225\u201345. https:\/\/doi.org\/10.1038\/s41580-019-0190-7.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1174_CR95","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2015.03.002","volume":"21","author":"F Bovenga","year":"2015","unstructured":"Bovenga F, Sabb\u00e0 C, Moschetta A. Uncoupling nuclear receptor LXR and cholesterol metabolism in cancer. Cell Metab. 2015;21:517\u201326. https:\/\/doi.org\/10.1016\/j.cmet.2015.03.002.","journal-title":"Cell Metab"},{"key":"1174_CR96","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1073\/pnas.0700899104","volume":"104","author":"A Radhakrishnan","year":"2007","unstructured":"Radhakrishnan A, Ikeda Y, Kwon HJ, et al. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci. 2007;104:6511\u20138. https:\/\/doi.org\/10.1073\/pnas.0700899104.","journal-title":"Proc Natl Acad Sci"},{"key":"1174_CR97","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1146\/annurev.physiol.68.033104.152158","volume":"68","author":"NY Kalaany","year":"2006","unstructured":"Kalaany NY, Mangelsdorf DJ. LXRS AND FXR: the Yin and Yang of cholesterol and fat metabolism. Annu Rev Physiol. 2006;68:159\u201391. https:\/\/doi.org\/10.1146\/annurev.physiol.68.033104.152158.","journal-title":"Annu Rev Physiol"},{"key":"1174_CR98","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/blood.2021012788","volume":"139","author":"A Brendolan","year":"2022","unstructured":"Brendolan A, Russo V. Targeting cholesterol homeostasis in hematopoietic malignancies. Blood. 2022;139:165\u201376. https:\/\/doi.org\/10.1182\/blood.2021012788.","journal-title":"Blood"},{"key":"1174_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2020.00516","author":"E Di Bello","year":"2020","unstructured":"Di Bello E, Zwergel C, Mai A, Valente S. The innovative potential of statins in cancer: new targets for new therapies. Front Chem. 2020. https:\/\/doi.org\/10.3389\/fchem.2020.00516.","journal-title":"Front Chem"},{"key":"1174_CR100","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1182\/blood-2003-03-0970","volume":"102","author":"NWCJ van de Donk","year":"2003","unstructured":"van de Donk NWCJ, Kamphuis MMJ, van Kessel B, et al. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood. 2003;102:3354\u201362. https:\/\/doi.org\/10.1182\/blood-2003-03-0970.","journal-title":"Blood"},{"key":"1174_CR101","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/ijms24010111","volume":"24","author":"SL Haney","year":"2022","unstructured":"Haney SL, Holstein SA. Targeting the isoprenoid biosynthetic pathway in multiple myeloma. Int J Mol Sci. 2022;24:111. https:\/\/doi.org\/10.3390\/ijms24010111.","journal-title":"Int J Mol Sci"},{"key":"1174_CR102","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","volume":"34","author":"KM Sanfilippo","year":"2016","unstructured":"Sanfilippo KM, Keller J, Gage BF, et al. Statins are associated with reduced mortality in multiple myeloma. J Clin Oncol. 2016;34:4008\u201314. https:\/\/doi.org\/10.1200\/JCO.2016.68.3482.","journal-title":"J Clin Oncol"},{"key":"1174_CR103","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","volume":"119","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood. 2012;119:5374\u201383. https:\/\/doi.org\/10.1182\/blood-2011-11-392522.","journal-title":"Blood"},{"key":"1174_CR104","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1182\/blood-2002-11-3359","volume":"102","author":"R Kurzrock","year":"2003","unstructured":"Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003;102:4527\u201334. https:\/\/doi.org\/10.1182\/blood-2002-11-3359.","journal-title":"Blood"},{"key":"1174_CR105","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/1078-0432.CCR-05-1792","volume":"12","author":"N Yanamandra","year":"2006","unstructured":"Yanamandra N, Colaco NM, Parquet NA, et al. Tipifarnib and Bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid Leukemia. Clin Cancer Res. 2006;12:591\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1792.","journal-title":"Clin Cancer Res"},{"key":"1174_CR106","doi-asserted-by":"publisher","first-page":"48213","DOI":"10.1074\/jbc.M106473200","volume":"276","author":"FP Coxon","year":"2001","unstructured":"Coxon FP, Helfrich MH, Larijani B, et al. Identification of a novel phosphonocarboxylate inhibitor of Rab Geranylgeranyl transferase that specifically prevents Rab Prenylation in osteoclasts and macrophages. J Biol Chem. 2001;276:48213\u201322. https:\/\/doi.org\/10.1074\/jbc.M106473200.","journal-title":"J Biol Chem"},{"key":"1174_CR107","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1021\/acsmedchemlett.5b00334","volume":"6","author":"VS Wills","year":"2015","unstructured":"Wills VS, Allen C, Holstein SA, Wiemer DF. Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase. ACS Med Chem Lett. 2015;6:1195\u20138. https:\/\/doi.org\/10.1021\/acsmedchemlett.5b00334.","journal-title":"ACS Med Chem Lett"},{"key":"1174_CR108","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1021\/acs.jmedchem.8b00886","volume":"61","author":"CM Lacbay","year":"2018","unstructured":"Lacbay CM, Waller DD, Park J, et al. Unraveling the prenylation-cancer paradox in multiple myeloma with novel geranylgeranyl pyrophosphate synthase (GGPPS) inhibitors. J Med Chem. 2018;61:6904\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00886.","journal-title":"J Med Chem"},{"key":"1174_CR109","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3109\/10428194.2012.752485","volume":"54","author":"RJ Watters","year":"2013","unstructured":"Watters RJ, Fox TE, Tan S-F, et al. Targeting glucosylceramide synthase synergizes with C 6 -ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. Leuk Lymphoma. 2013;54:1288\u201396. https:\/\/doi.org\/10.3109\/10428194.2012.752485.","journal-title":"Leuk Lymphoma"},{"key":"1174_CR110","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejbas.2018.10.003","volume":"5","author":"M Mashhadi Akbar Boojar","year":"2018","unstructured":"Mashhadi Akbar Boojar M, Mashhadi Akbar Boojar M, Golmohammad S. Ceramide pathway: a novel approach to cancer chemotherapy. Egypt J Basic Appl Sci. 2018;5:237\u201344. https:\/\/doi.org\/10.1016\/j.ejbas.2018.10.003.","journal-title":"Egypt J Basic Appl Sci"},{"key":"1174_CR111","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nature13475","volume":"510","author":"M Maceyka","year":"2014","unstructured":"Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014;510:58\u201367. https:\/\/doi.org\/10.1038\/nature13475.","journal-title":"Nature"},{"key":"1174_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.925807","author":"DN Petrusca","year":"2022","unstructured":"Petrusca DN, Lee KP, Galson DL. Role of sphingolipids in multiple myeloma progression, drug resistance, and their potential as therapeutic targets. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.925807.","journal-title":"Front Oncol"},{"key":"1174_CR113","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B Ogretmen","year":"2018","unstructured":"Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18:33\u201350. https:\/\/doi.org\/10.1038\/nrc.2017.96.","journal-title":"Nat Rev Cancer"},{"key":"1174_CR114","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1194\/jlr.R046656","volume":"55","author":"K Takabe","year":"2014","unstructured":"Takabe K, Spiegel S. Export of sphingosine-1-phosphate and cancer progression. J Lipid Res. 2014;55:1839\u201346. https:\/\/doi.org\/10.1194\/jlr.R046656.","journal-title":"J Lipid Res"},{"key":"1174_CR115","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11010-016-2854-3","volume":"424","author":"D Fu","year":"2017","unstructured":"Fu D, Li Y, Li J, et al. The effect of S1P receptor signaling pathway on the survival and drug resistance in multiple myeloma cells. Mol Cell Biochem. 2017;424:185\u201393. https:\/\/doi.org\/10.1007\/s11010-016-2854-3.","journal-title":"Mol Cell Biochem"},{"key":"1174_CR116","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/cancers14030772","volume":"14","author":"DN Petrusca","year":"2022","unstructured":"Petrusca DN, Mulcrone PL, Macar DA, et al. GFI1-dependent repression of SGPP1 increases multiple myeloma cell survival. Cancers (Basel). 2022;14:772. https:\/\/doi.org\/10.3390\/cancers14030772.","journal-title":"Cancers (Basel)"},{"key":"1174_CR117","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/ol.2022.13231","volume":"23","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Okabe S, Ohyashiki K, Gotoh A. Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment. Oncol Lett. 2022;23:111. https:\/\/doi.org\/10.3892\/ol.2022.13231.","journal-title":"Oncol Lett"},{"key":"1174_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2021.11.009","volume":"24","author":"MK Bennett","year":"2022","unstructured":"Bennett MK, Li M, Tea MN, et al. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition. Neoplasia. 2022;24:1\u201311. https:\/\/doi.org\/10.1016\/j.neo.2021.11.009.","journal-title":"Neoplasia"},{"key":"1174_CR119","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1182\/blood-2014-03-559385","volume":"124","author":"J Kummetha Venkata","year":"2014","unstructured":"Kummetha Venkata J, An N, Stuart R, et al. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood. 2014;124:1915\u201325. https:\/\/doi.org\/10.1182\/blood-2014-03-559385.","journal-title":"Blood"},{"key":"1174_CR120","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2006.02.017","volume":"42","author":"C Jakob","year":"2006","unstructured":"Jakob C, Sterz J, Zavrski I, et al. Angiogenesis in multiple myeloma. Eur J Cancer. 2006;42:1581\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2006.02.017.","journal-title":"Eur J Cancer"},{"key":"1174_CR121","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1172\/JCI10905","volume":"106","author":"Y Liu","year":"2000","unstructured":"Liu Y, Wada R, Yamashita T, et al. Edg-1, the G protein\u2013coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Investig. 2000;106:951\u201361. https:\/\/doi.org\/10.1172\/JCI10905.","journal-title":"J Clin Investig"},{"key":"1174_CR122","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1615\/CritRevOncog.2013006061","volume":"18","author":"R Ayto","year":"2013","unstructured":"Ayto R, Hughes DA. Gaucher disease and myeloma. Crit Rev Oncog. 2013;18:247\u201368. https:\/\/doi.org\/10.1615\/CritRevOncog.2013006061.","journal-title":"Crit Rev Oncog"},{"key":"1174_CR123","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1124\/jpet.103.062760","volume":"309","author":"AP Struckhoff","year":"2004","unstructured":"Struckhoff AP, Bittman R, Burow ME, et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther. 2004;309:523\u201332. https:\/\/doi.org\/10.1124\/jpet.103.062760.","journal-title":"J Pharmacol Exp Ther"},{"key":"1174_CR124","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cancers11121823","volume":"11","author":"S Faict","year":"2019","unstructured":"Faict S, Oudaert I, D\u2019Auria L, et al. The transfer of sphingomyelinase contributes to drug resistance in multiple myeloma. Cancers (Basel). 2019;11:1823. https:\/\/doi.org\/10.3390\/cancers11121823.","journal-title":"Cancers (Basel)"},{"key":"1174_CR125","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12967-020-02468-9","volume":"18","author":"L Liu","year":"2020","unstructured":"Liu L, Ye Q, Liu L, et al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b\/Akt pathway. J Transl Med. 2020;18:298. https:\/\/doi.org\/10.1186\/s12967-020-02468-9.","journal-title":"J Transl Med"},{"key":"1174_CR126","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/jcp.24306","volume":"228","author":"M Rossi","year":"2013","unstructured":"Rossi M, Pitari MR, Amodio N, et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2013;228:1506\u201315. https:\/\/doi.org\/10.1002\/jcp.24306.","journal-title":"J Cell Physiol"},{"key":"1174_CR127","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.4161\/cc.26585","volume":"12","author":"N Amodio","year":"2013","unstructured":"Amodio N, Bellizzi D, Leotta M, et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013;12:3650\u201362. https:\/\/doi.org\/10.4161\/cc.26585.","journal-title":"Cell Cycle"},{"key":"1174_CR128","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/leu.2017.336","volume":"32","author":"C Botta","year":"2018","unstructured":"Botta C, Cuc\u00e8 M, Pitari MR, et al. MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells. Leukemia. 2018;32:1003\u201315. https:\/\/doi.org\/10.1038\/leu.2017.336.","journal-title":"Leukemia"},{"key":"1174_CR129","doi-asserted-by":"publisher","first-page":"106527","DOI":"10.18632\/oncotarget.22507","volume":"8","author":"MA Stamato","year":"2017","unstructured":"Stamato MA, Juli G, Romeo E, et al. Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. Oncotarget. 2017;8:106527\u201337. https:\/\/doi.org\/10.18632\/oncotarget.22507.","journal-title":"Oncotarget"},{"key":"1174_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22403","author":"GD Roodman","year":"2009","unstructured":"Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem. 2009. https:\/\/doi.org\/10.1002\/jcb.22403.","journal-title":"J Cell Biochem"},{"key":"1174_CR131","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ctrv.2011.12.007","volume":"38","author":"M Zangari","year":"2012","unstructured":"Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in myeloma\u2014a review of current evidence. Cancer Treat Rev. 2012;38:968\u201380. https:\/\/doi.org\/10.1016\/j.ctrv.2011.12.007.","journal-title":"Cancer Treat Rev"},{"key":"1174_CR132","doi-asserted-by":"publisher","first-page":"46031","DOI":"10.1074\/jbc.M104464200","volume":"276","author":"T Iwamoto","year":"2001","unstructured":"Iwamoto T, Fukumoto S, Kanaoka K, et al. Lactosylceramide Is essential for the osteoclastogenesis mediated by macrophage-colony-stimulating factor and receptor activator of nuclear factor-\u03baB ligand. J Biol Chem. 2001;276:46031\u20138. https:\/\/doi.org\/10.1074\/jbc.M104464200.","journal-title":"J Biol Chem"},{"key":"1174_CR133","doi-asserted-by":"publisher","first-page":"18573","DOI":"10.1074\/jbc.M212626200","volume":"278","author":"H Ha","year":"2003","unstructured":"Ha H, Kwak HB, Lee SK, et al. Membrane rafts play a crucial role in receptor activator of nuclear factor \u03baB signaling and osteoclast function. J Biol Chem. 2003;278:18573\u201380. https:\/\/doi.org\/10.1074\/jbc.M212626200.","journal-title":"J Biol Chem"},{"key":"1174_CR134","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1254\/jphs.FMJ05004X3","volume":"100","author":"S Fukumoto","year":"2006","unstructured":"Fukumoto S, Iwamoto T, Sakai E, et al. Current topics in pharmacological research on bone metabolism: osteoclast differentiation regulated by glycosphingolipids. J Pharmacol Sci. 2006;100:195\u2013200. https:\/\/doi.org\/10.1254\/jphs.FMJ05004X3.","journal-title":"J Pharmacol Sci"},{"key":"1174_CR135","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1172\/JCI59987","volume":"125","author":"A Ersek","year":"2015","unstructured":"Ersek A, Xu K, Antonopoulos A, et al. Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. J Clin Investig. 2015;125:2279\u201392. https:\/\/doi.org\/10.1172\/JCI59987.","journal-title":"J Clin Investig"},{"key":"1174_CR136","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s40265-014-0296-3","volume":"74","author":"RM Poole","year":"2014","unstructured":"Poole RM. Eliglustat: first global approval. Drugs. 2014;74:1829\u201336. https:\/\/doi.org\/10.1007\/s40265-014-0296-3.","journal-title":"Drugs"},{"key":"1174_CR137","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.1038\/s41467-022-35358-3","volume":"13","author":"H Leng","year":"2022","unstructured":"Leng H, Zhang H, Li L, et al. Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease. Nat Commun. 2022;13:7868. https:\/\/doi.org\/10.1038\/s41467-022-35358-3.","journal-title":"Nat Commun"},{"key":"1174_CR138","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.3390\/cancers13143461","volume":"13","author":"Z Matula","year":"2021","unstructured":"Matula Z, Mikala G, Luk\u00e1csi S, et al. Stromal cells serve drug resistance for multiple myeloma via mitochondrial transfer: a study on primary myeloma and stromal cells. Cancers (Basel). 2021;13:3461. https:\/\/doi.org\/10.3390\/cancers13143461.","journal-title":"Cancers (Basel)"},{"key":"1174_CR139","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1158\/0008-5472.CAN-18-0773","volume":"79","author":"CR Marlein","year":"2019","unstructured":"Marlein CR, Piddock RE, Mistry JJ, et al. CD38-driven mitochondrial trafficking promotes bioenergetic plasticity in multiple myeloma. Cancer Res. 2019;79:2285\u201397. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0773.","journal-title":"Cancer Res"},{"key":"1174_CR140","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.584683","author":"H Fairfield","year":"2021","unstructured":"Fairfield H, Costa S, Falank C, et al. Multiple myeloma cells alter adipogenesis, increase senescence-related and inflammatory gene transcript expression, and alter metabolism in preadipocytes. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2020.584683.","journal-title":"Front Oncol"},{"key":"1174_CR141","doi-asserted-by":"publisher","first-page":"45305","DOI":"10.1038\/srep45305","volume":"7","author":"X Qin","year":"2017","unstructured":"Qin X, Lin L, Cao L, et al. Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis. Sci Rep. 2017;7:45305. https:\/\/doi.org\/10.1038\/srep45305.","journal-title":"Sci Rep"},{"key":"1174_CR142","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/cancers13030364","volume":"13","author":"MR Reagan","year":"2021","unstructured":"Reagan MR, Fairfield H, Rosen CJ. Bone marrow adipocytes: a link between obesity and bone cancer. Cancers (Basel). 2021;13:364. https:\/\/doi.org\/10.3390\/cancers13030364.","journal-title":"Cancers (Basel)"},{"key":"1174_CR143","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/sj.leu.2404466","volume":"21","author":"B Arnulf","year":"2007","unstructured":"Arnulf B, Lecourt S, Soulier J, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 2007;21:158\u201363. https:\/\/doi.org\/10.1038\/sj.leu.2404466.","journal-title":"Leukemia"},{"key":"1174_CR144","doi-asserted-by":"publisher","first-page":"34329","DOI":"10.18632\/oncotarget.6020","volume":"6","author":"Z Liu","year":"2015","unstructured":"Liu Z, Xu J, He J, et al. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 2015;6:34329\u201341. https:\/\/doi.org\/10.18632\/oncotarget.6020.","journal-title":"Oncotarget"},{"key":"1174_CR145","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/jbmr.3951","volume":"35","author":"EV Morris","year":"2020","unstructured":"Morris EV, Suchacki KJ, Hocking J, et al. Myeloma cells down-regulate adiponectin in bone marrow adipocytes via TNF-alpha. J Bone Miner Res. 2020;35:942\u201355. https:\/\/doi.org\/10.1002\/jbmr.3951.","journal-title":"J Bone Miner Res"},{"key":"1174_CR146","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau9087","author":"H Liu","year":"2019","unstructured":"Liu H, He J, Koh SP, et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med. 2019. https:\/\/doi.org\/10.1126\/scitranslmed.aau9087.","journal-title":"Sci Transl Med"},{"key":"1174_CR147","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark C, Holmberg E, Mellqvist U-H, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313. https:\/\/doi.org\/10.3324\/haematol.2014.107714.","journal-title":"Haematologica"},{"key":"1174_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.606368","author":"L Yamamoto","year":"2021","unstructured":"Yamamoto L, Amodio N, Gulla A, Anderson KC. Harnessing the immune system against multiple myeloma: challenges and opportunities. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2020.606368.","journal-title":"Front Oncol"},{"key":"1174_CR149","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1080\/10428194.2017.1337115","volume":"59","author":"MHZ Guang","year":"2018","unstructured":"Guang MHZ, McCann A, Bianchi G, et al. Overcoming multiple myeloma drug resistance in the era of cancer \u2018omics.\u2019 Leuk Lymphoma. 2018;59:542\u201361. https:\/\/doi.org\/10.1080\/10428194.2017.1337115.","journal-title":"Leuk Lymphoma"},{"key":"1174_CR150","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","volume":"121","author":"GT G\u00f6rg\u00fcn","year":"2013","unstructured":"G\u00f6rg\u00fcn GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121:2975\u201387. https:\/\/doi.org\/10.1182\/blood-2012-08-448548.","journal-title":"Blood"},{"key":"1174_CR151","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s41375-020-0947-1","volume":"35","author":"M Rossi","year":"2021","unstructured":"Rossi M, Altomare E, Botta C, et al. miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma. Leukemia. 2021;35:823\u201334. https:\/\/doi.org\/10.1038\/s41375-020-0947-1.","journal-title":"Leukemia"},{"key":"1174_CR152","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009890","author":"N Gudgeon","year":"2023","unstructured":"Gudgeon N, Giles HV, Bishop EL, et al. Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma. Blood Adv. 2023. https:\/\/doi.org\/10.1182\/bloodadvances.2023009890.","journal-title":"Blood Adv"},{"key":"1174_CR153","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma X, Xiao L, Liu L, et al. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33:1001-1012.e5. https:\/\/doi.org\/10.1016\/j.cmet.2021.02.015.","journal-title":"Cell Metab"},{"key":"1174_CR154","doi-asserted-by":"publisher","first-page":"9489","DOI":"10.1096\/fj.201900319R","volume":"33","author":"MT Bilotta","year":"2019","unstructured":"Bilotta MT, Abruzzese MP, Molfetta R, et al. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms. FASEB J. 2019;33:9489\u2013504. https:\/\/doi.org\/10.1096\/fj.201900319R.","journal-title":"FASEB J"},{"key":"1174_CR155","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00204-010-0609-6","volume":"85","author":"M Mamas","year":"2011","unstructured":"Mamas M, Dunn WB, Neyses L, Goodacre R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol. 2011;85:5\u201317. https:\/\/doi.org\/10.1007\/s00204-010-0609-6.","journal-title":"Arch Toxicol"},{"key":"1174_CR156","doi-asserted-by":"publisher","first-page":"118852","DOI":"10.1016\/j.lfs.2020.118852","volume":"265","author":"F Fei","year":"2021","unstructured":"Fei F, Ma T, Zhou X, et al. Metabolic markers for diagnosis and risk-prediction of multiple myeloma. Life Sci. 2021;265:118852. https:\/\/doi.org\/10.1016\/j.lfs.2020.118852.","journal-title":"Life Sci"},{"key":"1174_CR157","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.leukres.2014.12.010","volume":"39","author":"A Jurczyszyn","year":"2015","unstructured":"Jurczyszyn A, Czepiel J, Gdula-Argasi\u0144ska J, et al. Plasma fatty acid profile in multiple myeloma patients. Leuk Res. 2015;39:400\u20135. https:\/\/doi.org\/10.1016\/j.leukres.2014.12.010.","journal-title":"Leuk Res"},{"key":"1174_CR158","doi-asserted-by":"publisher","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-12-2917","volume":"19","author":"L Puchades-Carrasco","year":"2013","unstructured":"Puchades-Carrasco L, Lecumberri R, Mart\u00ednez-L\u00f3pez J, et al. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res. 2013;19:4770\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2917.","journal-title":"Clin Cancer Res"},{"key":"1174_CR159","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.7150\/jca.69321","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Chen B, Shao R, et al. A new prediction model integrated serum lipid profile for patients with multiple myeloma. J Cancer. 2022;13:1796\u2013807. https:\/\/doi.org\/10.7150\/jca.69321.","journal-title":"J Cancer"},{"key":"1174_CR160","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1111\/cas.14178","volume":"110","author":"K Maekawa","year":"2019","unstructured":"Maekawa K, Ri M, Nakajima M, et al. Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma. Cancer Sci. 2019;110:3267\u201374. https:\/\/doi.org\/10.1111\/cas.14178.","journal-title":"Cancer Sci"},{"key":"1174_CR161","doi-asserted-by":"publisher","first-page":"e0202045","DOI":"10.1371\/journal.pone.0202045","volume":"13","author":"N Steiner","year":"2018","unstructured":"Steiner N, M\u00fcller U, Hajek R, et al. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets. PLoS ONE. 2018;13:e0202045. https:\/\/doi.org\/10.1371\/journal.pone.0202045.","journal-title":"PLoS ONE"},{"key":"1174_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157969","author":"L Bao","year":"2023","unstructured":"Bao L, Wang Y, Lu M, et al. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis. Front Endocrinol (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1157969.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1174_CR163","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.3390\/ijms222212234","volume":"22","author":"E Logie","year":"2021","unstructured":"Logie E, Van Puyvelde B, Cuypers B, et al. Ferroptosis induction in multiple myeloma cells triggers DNA methylation and histone modification changes associated with cellular senescence. Int J Mol Sci. 2021;22:12234. https:\/\/doi.org\/10.3390\/ijms222212234.","journal-title":"Int J Mol Sci"},{"key":"1174_CR164","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0145-2126(02)00085-1","volume":"27","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Appelbaum FR, Willman CL, et al. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res. 2003;27:133\u201345. https:\/\/doi.org\/10.1016\/S0145-2126(02)00085-1.","journal-title":"Leuk Res"},{"key":"1174_CR165","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1182\/blood-2002-07-2283","volume":"101","author":"HY Li","year":"2003","unstructured":"Li HY, Appelbaum FR, Willman CL, et al. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003;101:3628\u201334. https:\/\/doi.org\/10.1182\/blood-2002-07-2283.","journal-title":"Blood"},{"key":"1174_CR166","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1002\/eji.201344292","volume":"44","author":"C Traversari","year":"2014","unstructured":"Traversari C, Sozzani S, Steffensen KR, Russo V. LXR-dependent and -independent effects of oxysterols on immunity and tumor growth. Eur J Immunol. 2014;44:1896\u2013903. https:\/\/doi.org\/10.1002\/eji.201344292.","journal-title":"Eur J Immunol"},{"key":"1174_CR167","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1158\/1535-7163.MCT-13-0997","volume":"13","author":"JR Agarwal","year":"2014","unstructured":"Agarwal JR, Wang Q, Tanno T, et al. Activation of liver X receptors inhibits hedgehog signaling, clonogenic growth, and self-renewal in multiple myeloma. Mol Cancer Ther. 2014;13:1873\u201381. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0997.","journal-title":"Mol Cancer Ther"},{"key":"1174_CR168","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature17412","volume":"531","author":"W Yang","year":"2016","unstructured":"Yang W, Bai Y, Xiong Y, et al. Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism. Nature. 2016;531:651\u20135. https:\/\/doi.org\/10.1038\/nature17412.","journal-title":"Nature"},{"key":"1174_CR169","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ctrv.2018.06.010","volume":"69","author":"MI Abdullah","year":"2018","unstructured":"Abdullah MI, de Wolf E, Jawad MJ, Richardson A. The poor design of clinical trials of statins in oncology may explain their failure\u2014lessons for drug repurposing. Cancer Treat Rev. 2018;69:84\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.010.","journal-title":"Cancer Treat Rev"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01174-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T05:36:07Z","timestamp":1698816967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":169,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01174-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,28]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing or financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable to this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable to this article, as it is a literature review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}